upacicalcet
Secondary Hyperparathyroidism (SHPT) in patients receiving hemodialysis
Phase 3Active
Key Facts
Indication
Secondary Hyperparathyroidism (SHPT) in patients receiving hemodialysis
Phase
Phase 3
Status
Active
Company
About Pathalys Pharma
Pathalys Pharma is a late-stage biotech company targeting critical unmet needs in end-stage chronic kidney disease, with its lead program, upacicalcet, in Phase 3 development for secondary hyperparathyroidism (SHPT). The company is well-capitalized, having secured a $105 million Series B financing in August 2024 to fund its NDA submission and pre-commercialization efforts. With a strategic focus on the dialysis patient population and backing from key industry investors, Pathalys is positioned to advance a pipeline of potential therapeutics for this underserved patient group.
View full company profile